V-Bio Ventures
Shelley Margetson joined V-Bio Ventures in December 2020 as Managing Partner.
Prior to joining V-Bio Ventures, Shelley spent over 20 years in executive roles in both finance and business, across a wide range of various European biotechnology companies. As CFO of Merus (MRUS) she managed the Initial Public Offering on the Nasdaq in May 2016 and as CEO of Gadeta she closed a ‘build to buy’ deal with Kite/Gilead. Shelley has managed multiple funding rounds, business exits and negotiated multiple international business transactions, spanning three continents.
Shelley has a finance/business background, holds a BA in business economics and is a member of the Chartered Institute of Management Accountants.
V-Bio Ventures
V-Bio Ventures is a venture capital fund that finds, builds, and finances young, innovative companies in the life sciences arena. They invest throughout Europe in start-up and early-stage companies with high growth potential. They focus on technologies that provide transformational improvements in the biopharmaceutical, pharmaceutical, diagnostics, and agricultural sectors.